Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking

被引:29
|
作者
Bathelt, C [1 ]
Schmid, RD [1 ]
Pleiss, J [1 ]
机构
[1] Univ Stuttgart, Inst Tech Biochem, D-70569 Stuttgart, Germany
关键词
loop; MD simulation; P450; monooxygenase;
D O I
10.1007/s00894-002-0104-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human cytochrome P450 (CYP) 2B6 activates the anticancer prodrug cyclophosphamide (CPA) by 4-hydroxylation. In contrast, the same enzyme catalyzes N-deethylation of a structural isomer, the prodrug ifosfamide (IFA), thus causing severe adverse drug effects. To model the molecular interactions leading to a switch in regioselectivity, the structure of CYP2B6 was modeled based on the structure of rabbit CYP2C5. We modeled the missing 22-residue loop in CYP2C5 between helices F and G (the F G loop), which is not resolved in the Xray structure, by molecular dynamics (MD) simulations using a simulated annealing protocol. The modeled conformation of the loop was validated by unconstrained MD simulations of the complete enzymes (CYP2C5 and CYP2B6) in water for 70 and 120 ps, respectively. The simulations were stable and led to a backbone r.m.s. deviation of 1.7 Angstrom between the two CYPs. The shape of the substrate binding site of CYP2B6 was further analyzed. It consists of three well-defined hydrophobic binding pockets adjacent to the catalytic heme. Size, shape and hydrophobicity of these pockets were compared to the shapes of the two structurally isomeric substrates. In their preferred orientation in the binding site, both substrates fill all three binding pockets without repulsive interactions. The distance to the heme iron is short enough for 4-hydroxylation and N-deethylation to occur for CPA and IFA, respectively. However, if the substrates are docked in the non-preferred orientation (such that 4-hydroxylation and N-deethylation would occur for IFA and CPA, respectively), one pocket is left empty, and clashes were observed between the substrates and the enzyme. Electronic supplementary material to this paper can be obtained by using the Springer Link server located at http://dx.doi.org/10.1007/s00894-002-0104-y.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 50 条
  • [31] DEC1 negatively regulates CYP2B6 expression by binding to the CYP2B6 promoter region ascribed to IL-6-induced downregulation of CYP2B6 expression in HeLa cells
    Luan, Xiaofei
    Zhao, Yi
    Bu, Na
    Chen, Yue
    Chen, Nan
    XENOBIOTICA, 2021, 51 (12) : 1343 - 1351
  • [32] The Influence of Sex, Ethnicity, and CYP2B6 Genotype on Bupropion Metabolism as an Index of Hepatic CYP2B6 Activity in Humans
    Ilic, Katarina
    Hawke, Roy L.
    Thirumaran, Ranjit K.
    Schuetz, Erin G.
    Hull, J. Heyward
    Kashuba, Angela D. M.
    Stewart, Paul W.
    Lindley, Celeste M.
    Chen, Mei-Ling
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (03) : 575 - 581
  • [33] Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling
    Spatzenegger, M
    Liu, H
    Wang, QM
    Debarber, A
    Koop, DR
    Halpert, JR
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (01): : 477 - 487
  • [34] Variants in the CYP2B6 3UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs
    Burgess, Kimberly S.
    Ipe, Joseph
    Swart, Marelize
    Metzger, Ingrid F.
    Lu, Jessica
    Gufford, Brandon T.
    Thong, Nancy
    Desta, Zeruesenay
    Gaedigk, Roger
    Pearce, Robin E.
    Gaedigk, Andrea
    Liu, Yunlong
    Skaar, Todd C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (01) : 130 - 138
  • [35] CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon
    Paganotti, Giacomo Maria
    Russo, Gianluca
    Sobze, Martin Sanou
    Mayaka, George Bouting
    Muthoga, Charles Waithaka
    Tawe, Leabaneng
    Martinelli, Axel
    Romano, Rita
    Vullo, Vincenzo
    INFECTION GENETICS AND EVOLUTION, 2015, 35 : 122 - 126
  • [36] Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study
    Dobrinas, Maria
    Crettol, Severine
    Oneda, Beatrice
    Lahyani, Rachel
    Rotger, Margalida
    Choong, Eva
    Lubomirov, Rubin
    Csajka, Chantal
    Eap, Chin B.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (02): : 84 - 93
  • [37] Synergistically Enhanced CYP2B6 Inducibility between a Polymorphic Mutation in CYP2B6 Promoter and Pregnane X Receptor Activation
    Li, Haishan
    Ferguson, Stephen S.
    Wang, Hongbing
    MOLECULAR PHARMACOLOGY, 2010, 78 (04) : 704 - 713
  • [38] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    Milcah Dhoro
    Simbarashe Zvada
    Bernard Ngara
    Charles Nhachi
    Gerald Kadzirange
    Prosper Chonzi
    Collen Masimirembwa
    BMC Pharmacology and Toxicology, 16
  • [39] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
    Dhoro, Milcah
    Zvada, Simbarashe
    Ngara, Bernard
    Nhachi, Charles
    Kadzirange, Gerald
    Chonzi, Prosper
    Masimirembwa, Collen
    BMC PHARMACOLOGY & TOXICOLOGY, 2015, 16
  • [40] Examination of purported probes of human CYP2B6
    Ekins, S
    VandenBranden, M
    Ring, BJ
    Wrighton, SA
    PHARMACOGENETICS, 1997, 7 (03): : 165 - 179